At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 19 enrolled
Drug / intervention
Pioglitazonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Pilot Study of Pioglitazone in Sporadic Inclusion Body Myositis
In Brief
A Phase 1 clinical trial evaluating Pioglitazone for Myositis and 5 related conditions. Completed, enrolled 19 participants across 1 site.
Detailed Summary
A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyositis, Inclusion Body Myositis, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMay 2018
Primary CompletionDec 2020
TodayJul 2026
First PostedFeb 20, 2018
Enrollment StartMay 22, 2018
Primary CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.4 years ago
Interventions
Pioglitazonedrug
Pioglitazone comes as a tablet to take by mouth and can be taken with or without food.